Abstract
Purpose of Review
To review the evidence for stopping antiviral therapy with nucleos(t)ide analogues (NA) in patients with chronic hepatitis B.
Recent Findings
HBsAg loss is usually stable even without anti-HBs seroconversion after stopping NA therapy. About 50% of HBeAg-positive patients who have achieved anti-HBe seroconversion and have stopped NA therapy remain in virological remission. Consolidation therapy increases the response rate. In HBeAg-negative hepatitis, stable virological remission is documented in 30% after NA discontinuation. Interestingly, some studies document unexpectedly high long-term HBsAg loss rates after stopping therapy.
Summary
Evidence supports NA discontinuation, especially after HBsAg seroclearance. In HBeAg-positive patients, NA can be stopped 12 months after anti-HBe seroconversion but severe flares have to be considered. NA discontinuation is also possible in selected HBeAg-negative patients if close monitoring can be guaranteed. The high rate of HBsAg loss needs further evaluation.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
EASL. 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
Terrault NA, Lok ASF, McMahon BJ, Chang K, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.
Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
• Liu J, Yang H, Lee M, Lu S, Jen C, Batrla-Utermann R, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014;63(10):1648–57 Describes the positive impact of HBsAg loss on HCC risk.
Kim G, Lee HC, Kim M, Ha Y, Park EJ, An J, et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol. 2015;62(5):1092–9.
Chen YC, Jeng WJ, Chien RN, Chu CM, Liaw YF. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection. Aliment Pharmacol Ther. 2016;43(12):1311–8.
•• Yeo YH, Ho HJ, Yang H, Tseng T, Hosaka T, Trinh HN, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156(3):63–646.e9 Comprehensive meta-analysis about clinical factors associated with HBsAg seroclearance.
Chi H, Wong D, Peng J, Cao J, Van Hees S, Vanwolleghem T, et al. Durability of response after hepatitis B surface antigen seroclearance during nucleos(t)ide analogue treatment in a multiethnic cohort of chronic hepatitis B patients: results after treatment cessation. Clin Infect Dis. 2017;65(4):680–3.
Kim G, Lim Y, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325–32.
• Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016;63(5):1481–92 Systematic review of stopping NA therapy in HBeAg positive and negative patients.
Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci U S A. 2004;101(2):638–40.
Nie H, Evans AA, London WT, Block TM, Ren XD. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol. 2012;56(4):795–802.
Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA, et al. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2015;41(9):867–76.
Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS ONE. 2013;8(7):e68568.
Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51(2):415–21.
• Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut. 2019; https://doi.org/10.1136/gutjnl-2019-318981. Largest prospective trial of stopping NA therapy. Did not show an effect on HBsAg.
Chang M, Liaw Y, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2015;42(3):243–57.
• Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, et al. Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients. J Infect Dis. 2018;218(9):1480–4 Head-to-head trial comparing relapse timings between ETV and TDF.
Kuo M, Hu T, Hung C, Wang J, Lu S, Tsai K, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther. 2019;49(2):218–28.
Su T, Yang H, Tseng T, Liou J, Liu C, Chen C, et al. Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy. J Infect Dis. 2018;217(8):1193–201.
Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, et al. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut. 2018;67(2):362–71.
Jeng W, Chen Y, Sheen I, Lin C, Hu T, Chien R, et al. Clinical relapse after cessation of tenofovir therapy in hepatitis B e antigen-negative patients. Clin Gastroenterol Hepatol. 2016;14(12):181–1820.e1.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, et al. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther (Lond ). 2018;23(8):677–85.
•• Berg T, Simon K, Mauss S, Schott E, Heyne R, Klass DM, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017;67(5):918–24 Prospective, randomized controlled study in Caucasian patients for stopping NA therapy.
Höner Zu Siederdissen C, Rinker F, Maasoumy B, Wiegand SB, Filmann N, Falk CS, et al. Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Infect Dis. 2016;214(10):1492–7.
Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology. 2012;143(3):62–636.e1.
• Jeng W, Chen Y, Chien R, Sheen I, Liaw Y. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B. Hepatology. 2018;68(2):425–34 NA stop in Asian patients and effects on HBsAg levels.
• Chen C, Hung C, Wang J, Lu S, Lai H, Hu T, et al. The incidence of hepatitis B surface antigen loss between hepatitis B E antigen-negative noncirrhotic patients who discontinued or continued entecavir therapy. J Infect Dis. 2019;219(10):1624–33 NA stop in Asian patients and effects on HBsAg levels.
Liaw Y, Jeng W, Chang M. HBsAg kinetics in retreatment decision for off-therapy hepatitis B flare in HBeAg-negative patients. Gastroenterology. 2018;154(8):2280–1.
Chang M, Liaw Y. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61(6):1407–17.
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81(8):4215–25.
Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143(4):96–973.e9.
• Rinker F, Zimmer CL, Höner Zu Siederdissen C, Manns MP, Kraft ARM, Wedemeyer H, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Hepatol. 2018;69(3):584–93 Importance of t-cells after stopping NA therapy.
Cornberg M, Manns MP. Hepatitis: no cure for hepatitis B and D without targeting integrated viral DNA? Nat Rev Gastroenterol Hepatol. 2018;15(4):195–6.
• Wooddell CI, Yuen M, Chan HL, Gish RG, Locarnini SA, Chavez D, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017;9(409). https://doi.org/10.1126/scitranslmed.aan0241. Influence of integrated HBV DNA for HBsAg production.
Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Invest. 2018;128(2):668–81.
Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, et al. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev. 2019;8(1):207.
Aguirre-Gamboa R, Joosten I, Urbano PCM, van der Molen RG, van Rijssen E, van Cranenbroek B, et al. Differential Effects of Environmental and Genetic Factors on T and B Cell Immune Traits. Cell Rep. 2016;17(9):2474–87.
Hung C, Wang J, Lu S, Hu T, Lee C, Chen C. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. J Viral Hepat. 2017;24(7):599–607.
Lampertico P, Berg T. Less can be more: a finite treatment approach for HBeAg-negative chronic hepatitis B. Hepatology. 2018;68(2):397–400.
Liu Y, Jia M, Wu S, Jiang W, Feng Y. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis. Int J Infect Dis. 2019;86:201–7.
Qiu Y, Huang L, Yang W, Wang Z, Zhang B, Li Y, et al. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis. 2016;43:43–8.
Yao C, Lee C, Hung C, Wang J, Hu T, Lu S, et al. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. J Gastroenterol Hepatol. 2015 May;30(5):918–24.
Yao C, Hung C, Hu T, Lu S, Wang J, Lee C, et al. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. Sci Rep. 2017;7(1):1839.
Luo H, Zhang X, Cao L, Tan N, Kang Q, Xi H, et al. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients. World J Gastroenterol. 2019;25(6):719–28.
Chen E, Wang M, Tao Y, Wu D, Liao J, He M, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat. 2019;26(5):586–95.
van Bömmel F, Bartens A, Mysickova A, Hofmann J, Krüger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61(1):66–76.
Carey I, Gersch J, Bruce M, Wang B, Moigboi C, Cloherty G, et al. Pre-genomic HBV RNA and HBcrAg play important role in the predicting clinical outcomes in chronic hepatitis B patients suppressed on antiviral therapy with nucleos (t)ide analogues. J Hepatol EASL Abstract. 2019;70(Supplement e33): 6.
Jung KS, Park JY, Chon YE, Kim H, Kang W, Kim BK, et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol. 2016;51(8):830–9.
Xia M, Liao G, Chen H, Wu Y, Fan R, Zhang X, et al. Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. Clin Immunol. 2019;198:31–8.
Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, et al. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat. 2019;26(6):697–709.
Zimmer CL, Rinker F, Höner Zu Siederdissen C, Manns MP, Wedemeyer H, Cornberg M, et al. Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss. J Infect Dis. 2018;217(10):1656–66.
Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007;15(4):143–6.
Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 2012;189(8):3925–35.
•• Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer. 2019;19(1):511 Highlights the potential effect of antiviral therapy in HCC development.
Jeng W, Sheen I, Chen Y, Hsu C, Chien R, Chu C, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013 Dec;58(6):1888–96.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Maximilian Wübbolding declares no potential conflicts of interest. Markus Cornberg reports personal fees for lectures and advisory boards from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag (Data Safety Board), Roche, Merck (MSD), Biogen, Falk Foundation, Boehringer Ingelheim, Siemens, and Spring Bank. Dr. Cornberg reports a grant from Roche. Christoph Höner zu Siederdissen reports travel grants from Gilead Sciences and Novartis.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Hepatitis B
Rights and permissions
About this article
Cite this article
Wübbolding, M., Cornberg, M. & Höner zu Siederdissen, C. Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. Curr Hepatology Rep 18, 512–521 (2019). https://doi.org/10.1007/s11901-019-00502-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11901-019-00502-z